ATE228005T1 - Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form - Google Patents

Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form

Info

Publication number
ATE228005T1
ATE228005T1 AT97942511T AT97942511T ATE228005T1 AT E228005 T1 ATE228005 T1 AT E228005T1 AT 97942511 T AT97942511 T AT 97942511T AT 97942511 T AT97942511 T AT 97942511T AT E228005 T1 ATE228005 T1 AT E228005T1
Authority
AT
Austria
Prior art keywords
formulations
crf
present
liquid form
improved stability
Prior art date
Application number
AT97942511T
Other languages
English (en)
Inventor
Bert Ho
Behzad Khosrovi
Pamela G Hirtzer
Original Assignee
Neurobiological Technologies I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurobiological Technologies I filed Critical Neurobiological Technologies I
Application granted granted Critical
Publication of ATE228005T1 publication Critical patent/ATE228005T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97942511T 1996-09-20 1997-09-17 Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form ATE228005T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/717,306 US5780431A (en) 1996-09-20 1996-09-20 Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
PCT/US1997/016420 WO1998011912A1 (en) 1996-09-20 1997-09-17 Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form

Publications (1)

Publication Number Publication Date
ATE228005T1 true ATE228005T1 (de) 2002-12-15

Family

ID=24881496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97942511T ATE228005T1 (de) 1996-09-20 1997-09-17 Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form

Country Status (9)

Country Link
US (1) US5780431A (de)
EP (1) EP0929314B1 (de)
JP (1) JP4147329B2 (de)
AT (1) ATE228005T1 (de)
AU (1) AU4419497A (de)
CA (1) CA2266666C (de)
DE (1) DE69717293T2 (de)
ES (1) ES2187820T3 (de)
WO (1) WO1998011912A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228771B1 (en) * 1998-05-15 2013-05-28 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
AU4685900A (en) 1999-04-30 2000-11-17 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
DE19930676B4 (de) * 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
DE10085144T1 (de) * 1999-10-28 2003-04-24 Inst Neftechimicheskogo Sintez Polypeptidkomposition
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
IL162796A0 (en) 2002-05-21 2005-11-20 Kenji Kangawa Medicinal compositions containing ghrelin
JP2006522133A (ja) * 2003-03-31 2006-09-28 アルザ・コーポレーション 非水性単一相の媒体、及び、そのような媒体を利用するフォーミュレーション
US10765747B2 (en) * 2004-04-02 2020-09-08 Swedish Orphan Biovitrum Ab (Publ) Methods of reducing aggregation of IL-1ra
WO2006022301A1 (ja) * 2004-08-24 2006-03-02 Daiichi Asubio Pharma Co., Ltd. 生理活性ペプチド液状製剤
WO2007020871A1 (ja) * 2005-08-12 2007-02-22 Astellas Pharma Inc. デプシペプチド含有注射液
EP2164522A2 (de) * 2007-05-25 2010-03-24 Neutron Ltd. Crf-konjugate mit verlängerten halbwertzeiten
EP2167079A4 (de) * 2007-06-14 2011-10-26 Neutron Ltd Steroidsparende verfahren zur behandlung von gehirnödem
JP2011519375A (ja) * 2008-04-30 2011-07-07 ニュートロン ロウ 癌治療のためのコルチコトロピン放出因子の使用法
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US8334281B2 (en) * 2008-12-22 2012-12-18 Evoke Pharma, Inc. Nasal formulations of metoclopramide
CA3047088A1 (en) 2016-12-15 2018-06-21 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236901A (en) * 1988-04-20 1993-08-17 Research Corporation Technologies, Inc. Treatment for irritable bowel syndrome
US5177060A (en) * 1990-01-09 1993-01-05 Regents Of The University Of California Anti-inflammatory peptides and treatment to inhibit vascular leakage in injured tissues
JPH09504792A (ja) * 1993-11-02 1997-05-13 ニューロバイオロジカル テクノロジイズ インコーポレイテッド 慢性関節リウマチに関する治療

Also Published As

Publication number Publication date
EP0929314A1 (de) 1999-07-21
JP4147329B2 (ja) 2008-09-10
DE69717293T2 (de) 2003-09-04
AU4419497A (en) 1998-04-14
WO1998011912A1 (en) 1998-03-26
DE69717293D1 (de) 2003-01-02
ES2187820T3 (es) 2003-06-16
JP2001500876A (ja) 2001-01-23
CA2266666A1 (en) 1998-03-26
US5780431A (en) 1998-07-14
CA2266666C (en) 2003-11-25
EP0929314B1 (de) 2002-11-20

Similar Documents

Publication Publication Date Title
ATE228005T1 (de) Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
EA200000629A1 (ru) Стабилизированные растворы терипаратида
DE69329367D1 (de) Wachstumshormon-enthaltendeproteinformulierung
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
RU94033520A (ru) Впрыскиваемый лецитиновый гель
LV10907A (lv) Interferona polietilenglikola atvasinajums
KR850007559A (ko) 조절 펩타이드의 삽입식 제형
DK1044015T3 (da) Formuleringer med amylinagonistpeptider og insulin
ATE65183T1 (de) Waesserige steroidformulierungen zur nasalen verabreichung.
EP0747092A3 (de) Lösungsflüssigkeit für durch Iontophorese zugeführte Medikamente
KR850004389A (ko) 경피침투가 증진된 생리학적 활성제제의 제조방법
DK1212039T3 (da) Sammensætning til inhalation omfattende delta-9-tetrahydrocannabinol i et semivandigt oplösningsmiddel
DE69531736D1 (de) Oxytetracyclin enthaltendes arzneimittel mit verzögerter wirksoffabgabe
ES2028917T3 (es) Un procedimiento para preparar una composicion farmaceutica inyectable estable.
FI962056A0 (fi) Uusi farmaseuttinen koostumus stabiilin jauheen valmistamiseksi, joka sisältää asetyylisalisyylihapon ja metoklopramidin yhdistelmän käsittävän aktiivisen aineosan
ES2051709T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica para uso parenteral que contiene calcitonina como el ingrediente activo.
EA200200415A1 (ru) Композиция фармацевтического носителя
DK0873134T3 (da) Langvarig frigørelsesformulering omfattende bovin væksthormon frigørende faktor
JPS5675423A (en) Physiologically active high polymer substance-containing composition for mucosa administration and its preparation
CO4370014A1 (es) Soluciones inyectables estables de diritromicina
CA2194576A1 (en) Long-acting oxytetracycline composition
RU97113620A (ru) Ранозаживляющая мазь "эпофен"
DE29909986U1 (de) Stabile Arzneilösung umfassend Epirubicin und Puffersubstanzen
JPS643123A (en) Remedy for skin inflammation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties